TABLE 3.
Parameter | ESA‐Naïve Studya | ESA‐Converted Studyb | ||
---|---|---|---|---|
Roxadustat 50 mg | Roxadustat 70 mg | All ESA‐Naïve | All ESA‐Converted | |
N = 37 | N = 37 | N = 74 | N = 163 | |
Weeks 18‐24 | ||||
n | 33 | 32 | 65 | 148 |
Mean (SD) | 2.29 (1.05) | 2.24 (1.01) | 2.26 (1.02) | −0.03 (0.90) |
Median | 2.40 | 2.25 | 2.30 | 0.00 |
Range | 0.2‐4.2 | 0.4‐4.5 | 0.2‐4.5 | −3.2 to 1.9 |
Weeks 46‐52 | ||||
n | — | — | — | 128 |
Mean (SD) | — | — | — | 0.12 (0.83) |
Median | — | — | — | 0.10 |
Range | — | — | — | −2.6 to 2.0 |
Abbreviations: ESA, erythropoiesis‐stimulating agent; Hb, hemoglobin.
The study duration was 24 weeks.
The study duration was 52 weeks.